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Incidental findings found in ‘‘healthy’’ volunteers during imaging
performed for research: current legal and ethical implications
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ABSTRACT. Incidental findings found in ‘‘healthy’’ volunteers during research imaging
are common and have important implications for study design and performance,
particularly in the areas of informed consent, subjects’ rights, clinical image analysis
and disclosure. In this study, we aimed to determine current practice and regulations
concerning information that should be given to research subjects when obtaining
consent, reporting of research images, who should be informed about any incidental
findings and the method of disclosure. We reviewed all UK, European and international
humanitarian, legal and ethical agencies’ guidance. We found that the guidance on
what constitutes incidental pathology, how to recognise it and what to do about it is
inconsistent between agencies, difficult to find and less complete in the UK than
elsewhere. Where given, guidance states that volunteers should be informed during
the consent process about how research images will be managed, whether a
mechanism exists for identifying incidental findings, arrangements for their disclosure,
the potential benefit or harm and therapeutic options. The effects of incidentally
discovered pathology on the individual can be complex and far-reaching. Radiologist
involvement in analysis of research images varies widely; many incidental findings
might therefore go unrecognised. In conclusion, guidance on the management of
research imaging is inconsistent, limited and does not address the interests of
volunteers. Improved standards to guide management of research images and
incidental findings are urgently required.
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An incidental finding in a ‘‘healthy’’ volunteer
participating in research imaging may be defined as ‘‘a
finding that has potential health or reproductive
importance which is discovered in the course of
conducting research, but is beyond the aims of the
study’’ [1]. A recent meta-analysis of 16 studies invol-
ving 19 559 participants found that the prevalence of
incidental findings on brain MRI was 2.7% [2]. With
body MRI, the prevalence is 12.8% [3], and with CT
colonoscopy extra-colonic incidental findings require
further investigation or medical or surgical intervention
in 5–8% [4]. Therefore, incidental findings are common
and have important implications for the process of
informed consent, the need for clinical analysis of
images, mechanisms and pathways for notification of
the subject and for the subject themselves.
Incidental findings could have serious implications for
health, employment and medical and life insurance and
for the volunteer’s state of mind. Furthermore, suspected
abnormalities incorrectly identified by non-radiologi-
cally trained researchers could cause unnecessary alarm
and upset to research volunteers. The analysis of
research images and contingencies for dealing with
incidental findings in the UK vary [3, 5, 6], although
the limited systematic evidence concerning (and demon-
strating) variation in practice is from overseas [7, 8]. This
variation may reflect the lack of coherent, easily
accessible guidelines and variations in existing guidance.
In our experience as a group of researchers spread
throughout the UK and imaging different organ systems,
the involvement of radiologists in UK imaging research
also varies widely, with much research being conducted
remotely from radiology departments and without
explicit mechanisms for expert image analysis.
Consequently, we have analysed UK, other European
and other international legal and ethical resources to
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determine whether there is any current guidance on the
clinical and governance implications of elements of
research imaging in normal subjects. Specifically we
asked four questions:
N What information regarding the identification of
incidental findings should be provided during the
consent process?
N Should radiologists routinely report research images?
N To whom should incidental findings be disclosed?
N How should disclosure occur?
Methods and materials
We examined all available documents from the UK
Department of Health (DoH) pertaining to the Research
Governance Framework [9], the DoH’s Governance
arrangements for National Health Service (NHS) research
ethics committees [10], and guidelines on research gover-
nance and practice produced by the General Medical
Council (GMC) [11], the Medical Research Council (MRC)
[12], the British Medical Association (BMA) [13] and the
National Research Ethics Service (NRES) [14]. We also
examined UK data protection law [15], European legisla-
tion [16, 17], international guidelines [18–20] and imaging
research guidelines published inmedical and legal journals
(e.g. Appendix A [21, 22]).
The Westlaw database was used with expert assistance
to search for relevant case law and legal journal articles
relating to the Data Protection Act 1998 and Article Eight
of the European Convention of Human Rights. The
PubMed and MEDLINE databases were searched for
articles published before April 2009 using the major topic
MeSH term ‘‘Incidental Findings’’. Articles on imaging
in symptomatic volunteers were excluded.
We extracted all relevant statements on consent,
disclosure of information to the subject and to medical
practitioners, expert examination of images, and whether
there was any organ system-specific or imaging moda-
lity-specific advice. We distinguished between guidance
and regulations that apply in the UK and those that apply
outside the UK.
Results
Consent
General principles
Consent by volunteers for participation in research is
required ethically and, in most cases, legally under the
Human Rights Act 1998 [13, 23], with additional condi-
tions for children or mentally incapacitated volunteers
[24–28]. Further guidance is available from organisations
including the BMA and the GMC [13, 28]. The Additional
Protocol to the Convention on Human Rights and Biomedicine
Concerning Biomedical Research, agreed by the Council of
Europe [17], requires written consent for participation in
research and is legally binding under international law.
The UK has not yet signed or ratified either the Additional
Protocol or the Convention to which it relates; as and when
this occurs, there is likely to be a corresponding
requirement that consent is in written format under UK
domestic legislation. The Council for International
Organizations of Medical Sciences (CIOMS), established
by the World Health Organization (WHO) and United
Nations Educational Scientific and Cultural Organization
(UNESCO), requires informed consent of the prospective
subject or, where an individual is not capable of giving
informed consent, the permission of a legally authorised
representative for all biomedical research involving
humans [18]. These ethical guidelines are convergent
with UK and European guidelines but are not, in
themselves, legally binding.
Consent relating to incidental findings in the UK
The UK DoH recommends that, through ethics com-
mittee approval, arrangements are made to ensure that
‘‘relevant’’ information is provided to participants [9] and
that ‘‘there are arrangements, if appropriate, for informing
the research participant’s general practitioner (GP),
including procedures for seeking the participant’s consent
to do so’’ [10]. The meanings of ‘‘relevant’’ and ‘‘appro-
priate’’ in this context are open to interpretation, and will
probably vary according to the requirements of indivi-
duals and the complexity of the procedures involved [11].
NRES includes the following explicit statements
relevant to incidental findings in its published guidance
on informed consent:
N ‘‘The subject must be adequately informed…of the
possible disadvantages and risks of taking part…any
risks, discomfort or inconvenience should be briefly
outlined…the potential participant should be told
what would happen if other conditions were dis-
covered of which he or she was unaware…the
published literature should be consulted and material
presented to likely participant groups to assess its
value…you should consider insurance issues and
whether patients should be informed that their
participation may affect insurance cover.
N Possible benefits should [also be outlined].
N You should explain if the participant’s GP (or health
care practitioner) needs to be notified of their
participation, and seek consent. You should explain
what information will be exchanged.
N [The participant should be told] how their confidenti-
ality will be safeguarded during and after the study…
You may wish to tell the participants how your
procedures for handling, processing, storage and
destruction of their data match the Caldicott princi-
ples and/or the Data Protection Act 1998…it must be
clear if the data is to be retained for use in future
studies and whether further [ethics committee]
approval will be sought.’’
The implications of the explicit instructions in the first
point above are that mechanisms must be in place to
identify and deal appropriately with incidental findings
in a sensitive way, and that research subjects should be
apprised of any insurance or other implications. Yet the
low level of clinical and radiological involvement in most
imaging research suggests that such mechanisms do not
exist in most research imaging centres. We discuss the
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final point concerning data handling in more detail in the
section on data protection. An example of informed
consent for neuroimaging research that addresses some
of these NRES recommendations is presented in
Appendix B [6].
Consent relating to incidental findings in Europe
The European Additional Protocol to the Convention
requires that research participants are given comprehen-
sible, documented information. Participants must be
specifically informed of ‘‘any harm, and the available
treatment’’ (but not explicitly regarding incidental
findings) ‘‘and the arrangements made for responding
to adverse events or the concerns of research partici-
pants’’. This implies that information must be provided
prior to the research examination on management
pathways in the event of incidental findings.
Consent relating to incidental findings
internationally
CIOMS guidelines require that, prior to obtaining
consent, the investigator must provide information
to the subject regarding incidental findings, including
risks and benefits, that incidental findings will be
disclosed, whether the investigator will be the subject’s
physician and ‘‘the extent of the investigator’s re-
sponsibility to provide medical services to the partici-
pant’’ [20]. The unofficial United States (US) ‘‘Working
Group on Incidental Findings in Brain Imaging
Research’’ recommended that statistics about the inci-
dence of unexpected findings and the proportion with
potential clinical significance should be offered during
the process of obtaining consent [29], which we have
summarised in Appendix C. However, surveys have
indicated that, in practice, adherence to both guidelines
was variable. For example, consent for brain MRI
research did not address processes for incidental find-
ings in one US university, where 6.6% of ‘‘healthy’’
volunteers required clinical follow-up [30]. An example
of the key points to be covered during the process
of obtaining informed consent suggested by the US
‘‘Working Group on Incidental Findings in Brain
Imaging Research’’ has since been published [22],
which incorporates all the CIOMS guidelines except
explicitly stating that incidental findings may have
benefits.
Consent regarding future re-examination of
imaging data
The evolution of new analysis methods and growing
bioinformatic capability increases the possibility that
imaging data will be re-analysed after the primary study
has finished. The NRES states that it must be clear if the
data is to be retained for use in future studies and
whether further ethics committee approval will be
sought. Some US authors take this a step further and
recommend consent for future re-contact should an
incidental finding be discovered in future re-analysis
[1]. This latter recommendation is not yet a precedent
and a recent study found that less than 5% of US
institutions currently specify this [7].
Radiologist reporting of research images
A spectrum of models for reporting of research images
by radiologists ranges from no radiology reporting at all,
to ‘‘reactive radiology’’ where suspicious findings
noticed by investigators are referred to a radiologist for
an opinion, ‘‘proactive radiology’’ where all research
images are reported and ‘‘very proactive radiology’’
where images additional to those required for the
research may be acquired routinely to improve detection
or characterisation of any incidental findings.
Advice and practice in the UK
The UK Medical Devices Agency (MDA) recommends
that all volunteer MRI examinations are routinely
reported by a radiologist [31]. There are no reliable data
on howmany UK institutions adhere to this guideline for
MRI, and there are no equivalent guidelines on reporting
of other imaging modalities used in research such as CT,
ultrasound and positron emission tomography (PET).
Indeed there are no reliable data from the UK on
radiological involvement in research image examination.
Advice and practice in the US
Surveys in the US showed that neuroradiologist
involvement in neuroimaging studies was an
Institutional Review Board (IRB) requirement at 22% of
research institutions [8]. Where it was not an IRB
requirement, the majority of investigators surveyed said
that, if they did notice something suspicious on imaging,
they would consult with a radiologist for confirmation
[32]. However, the clinically relevant images in such
examinations (e.g. functional MRI) were often very
limited, leading to the following typical statement on
functional MRI consent forms: ‘‘On occasion the inves-
tigator may notice a finding on an MRI scan that seems
abnormal. When this occurs, a neuroradiologist will be
consulted as to whether the finding merits further
investigation…Because the images collected in this study
do not comprise a proper clinical MRI series, these
images will not be made available for diagnostic
purposes’’ [32]. Very few (,5%) institutions recom-
mended checking whether an incidental finding was real
or significant with a radiologist before its disclosure
[7]. Moreover, the majority of the ‘‘Working Group on
Incidental Findings in Brain Imaging Research’’ sug-
gested that ‘‘reactive radiology’’ was necessary only if
the research protocol included a means of disclosure [29].
Legal and ethical attitudes
Some legal authorities have stated that the reactive
model ignores the duties owed to the subject in human
research and may invite litigation [33]. For both
medicolegal and ethical reasons, proactive involvement
of specialist radiologists in research has been advocated,
both for the detection of abnormalities and for their
appropriate follow-up [34, 35]. This may already be more
commonplace in some types of imaging research, for
example radiologist analysis of research CT colonogra-
phy for extra-colonic incidental findings [4]. Ethically, it
has been argued that, as research subjects tacitly entrust
a dimension of their health to the discretion of clinical
investigators when they consent to participate in
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research, ‘‘proactive radiology’’ should be an obligation
[36, 37]. One ethical counter-argument is that the
researchers’ duty is to research and not to promote
health [38] and, therefore, incidental findings are of no
consequence and can be ignored.
Volunteers’ attitudes
There is little information on what volunteers expect to
be done about incidental findings on research images.
Many volunteers may expect that expert examination of
research images is routine [39]. In one of the few studies
that has sought research volunteers’ opinions, the
majority of the volunteers in neuroimaging research
expected that their images would be examined and
medical anomalies disclosed to them [40], regardless of
what written information they were given during the
consent process or whether the research took place in a
medical or non-medical environment. At a SINAPSE
Collaboration (Scottish Imaging Network, A Platform for
Scientific Excellence) debate, all 70 attendants indicated
that, if participating in a research study, they would wish
to have their images examined by a radiologist, and any
incidental finding disclosed to them and discussed with
a responsible physician [41].
Do missed incidental findings cause harm?
The evidence base to support a ‘‘proactive’’ policy is
limited. A review in 2004 found no documented adverse
outcome due to a missed finding in the legal or medical
literature [8]. It has been argued, therefore, that routinely
reporting research images for incidental findings is not
an ethical imperative [36]; however, this information is
likely to be incomplete.
Practical considerations
The ‘‘reactive radiology’’ approach assumes that the
task of identifying abnormal findings is simple, yet this
may be a particularly difficult task for a researcher not
trained in radiology [39]. Also, ‘‘proactive radiology’’ is
limited as imaging protocols used in research are
frequently not optimal for detection of incidental disease.
For example, during functional MRI studies of the brain
in cognitive neuroscience research, only limited struc-
tural images are usually acquired, and these are
relatively insensitive to pathology. Similarly, research
CT colonography often employs low-dose techniques,
limiting evaluation of extra-colonic structures. An
explanation of the diagnostic limitations of research
imaging techniques may therefore be essential to the
consent process [4]. Routine additional imaging — ‘‘very
proactive radiology’’ — may increase sensitivity to
incidental findings [39]. However, this model would
increase cost and could be impractical, as in some
situations a substantial number of additional sequences
would be required. Nonetheless, research at the US
National Institute of Health follows this ‘‘very proactive’’
model [42], which at least one US litigation lawyer
argues should be standard practice [33].
It has been argued that it may be more appropriate to
have a menu of practical options for screening incidental
neuroimaging findings appropriate to different research
settings [22], ranging from no examination for incidental
findings through to a ‘‘very proactive’’ approach
depending on the circumstances. The US ‘‘Working
Group on Incidental Findings in Brain Imaging
Research‘‘ eventually concluded that strict regulations
for handling incidental findings are not appropriate
given the present state of knowledge [29]. Instead,
the authors advocated clear informed consent and
communication at disclosure, rather than a ‘‘one size fits
all’’ radiological examination option. In general, radi-
ological reporting of research images has considerable
cost implications, which are beyond the scope of the
present paper and vary with the healthcare and research
funding models in different countries. However, at least
some of these costs could be offset by discounts for
research, for imaging volume or by written acknowl-
edgment of the radiologist’s input. Full authorship on
resultant publications may be appropriate where the
radiologist is a full member of the research team [29, 30].
Disclosure
UK data protection legislation
The Data Protection Act 1998 [15] establishes the legal
framework for protection of personal data, with explicit
obligation to provide ‘‘data subjects’’ with information
about who is handling their personal data and for what
purposes. Volunteers must be informed if, for example,
the GP will be told of any abnormal findings or if a copy
of the imaging or a report is routinely added to the
hospital clinical records. Incidental findings fall within
the Act definition of ‘‘sensitive personal data’’, and
volunteers may need to give their explicit consent to the
disclosure of an incidental finding to themselves.
Although research exemptions exist, they are not
relevant to incidental findings which support decisions
relating to particular individuals [13]. For example, an
exemption cannot be used to prevent the volunteer
accessing any personal data that revealed incidental
findings. The Act underpins MRC and GMC guidance
[11, 43] and Research Governance Framework and NRES
requirements that research data will be appropriately
managed and can be disclosed only to authorised
persons such as researchers, sponsors, regulatory autho-
rities and auditors [9, 10, 13].
In the US, radiological research guidelines strongly
recommend that a Certificate of Confidentiality is
provided for research subjects involved in illegal
behaviour (e.g. neuroimaging in cocaine users). The
certificate is designed to allow investigators to refuse to
disclose research data with private identifiable informa-
tion to a civil or judicial authority, even when the data
are requested under the authority of a subpoena [21]. No
similar legally binding confidentiality agreement is
available in the UK.
Consequences of disclosure to the volunteer
The balance between the risk and benefit of disclosing
unexpected findings depends on the significance of
imaging findings in diagnosis of asymptomatic disease
and the impact of early intervention on outcome.
Early identification of an incidental finding might be of
unequivocal benefit to the patient if the condition is
treatable and early diagnosis improves outcome. For
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example, renal cell carcinoma is not uncommon in a
largely ‘‘healthy’’ population [44] and can be detected
earlier with imaging than at symptomatic presentation
[45–47] with significant improvement in prognosis
[48, 49]. In Japan, a reduction in renal cell carcinoma
mortality has been attributed to a rise in incidentally
discovered lesions [50]. A similar argument applies to
incidental abdominal aortic aneurysms larger than 5 cm
[51]. Many incidental neuroimaging findings are, how-
ever, of indeterminate clinical significance [36], with
poorly characterised natural history and unpredictable
individual outcomes [52]; thus, treatment is of question-
able benefit [39].
The adverse effects of disclosing incidental findings
include anxiety, which may be considered ‘‘unneces-
sary’’ if the incidental finding is subsequently shown to
have no clinical importance [1, 53]. Incidental findings
can also adversely affect medical and life insurance and
have implications for future employment. Harm may
also result from further investigation of indeterminate or
suspicious findings, including exposure to ionising
radiation or more invasive procedures such as biopsy
[54, 55] or unnecessary treatment. During follow-up of
indeterminate extra-cardiac findings in a prospective
cardiac CT study (n5966), each patient underwent
additional diagnostic investigations with an estimated
mean effective dose of 9.4 mSv; of these, 12% underwent
invasive diagnostic procedures such as transthoracic
biopsy or bronchoscopy [56]. Data from the Japanese
atomic bomb survivors [57–59] and radiation workers in
the nuclear industry [60, 61] show that ionised radiation
doses as low as 5 mSv may increase the risk of cancer.
With follow-up, none of the indeterminate findings
became clinically significant. The authors concluded that
such false-positive findings may lead to increased costs
(mean US$508 per patient with an indeterminate find-
ing), increase patient morbidity, reduce patient quality of
life and have no clear mortality benefit.
These problems are compounded by the rapid
advances in the sensitivity of imaging technology,
increasing the chances of discovering incidental findings
whilst experience in interpretation of findings of these
early pre-symptomatic pathologies remains limited [62].
When to disclose — ethical background
Advice on disclosure of incidental findings found on
imaging is inconsistent and incomplete. The obligation to
disclose research results to volunteers has been argued
forcefully for genetic research results [63] and is
increasingly suggested for other types of clinical research
data [64]. Some ethicists argue that the principles of
respect for persons, reciprocity, beneficence and justice
oblige researchers to offer results to research participants
[65]. Others argue that if the process of disclosure to
volunteers is inadequate, disclosure may not be the
ethical imperative. In genetic studies, researchers and
participants have highlighted the constraints of
embedded clinical services limited by funds [66], namely
delays in receiving test results and researchers demon-
strating insufficient clinical sensitivity towards subjects.
If disclosure is considered an ethical imperative, then
funding agencies must support satisfactory clinical
services [65].
When to disclose — UK advice
The DoH requires that ethics committees ensure that
there are ‘‘arrangements, if appropriate, for informing
the research participant’s GP’’ [10]. However, this
statement is ambiguous. ‘‘If appropriate’’ is not qualified
and it is unclear whether the GP is informed merely that
the participant has been involved in an imaging study or
whether the GP is informed of all results including
incidental findings. The NRES requires that processes for
dealing with incidental findings are incorporated in the
consent process, but does not mandate disclosure of
incidental findings to volunteers. The MDA recommends
disclosure when incidental findings are identified in all
volunteers undergoing MRI, followed by appropriate
onward clinical referral [31]. This recommendation is
concordant with the wishes of 100% of a sample of
potential volunteers [41]. There are no other explicit UK
recommendations to disclose incidental findings to
volunteers, except if the volunteer specifically requests
disclosure. Here they would have a right, under section
seven of the Data Protection Act, to have access to
incidental findings.
When to disclose — European and US advice
The European Additional Protocol to the Convention
(Article 27) states ‘‘If research gives rise to information of
relevance to the current or future health or quality of life
of research participants, this information must be offered
to them’’ [17]. Disclosing only ‘‘relevant’’ incidental
findings is a practical approach, as only a small
percentage of findings are clinically relevant [32].
However, it is uncertain how to determine reliably what
incidental finding is ‘‘relevant’’ for each research
participant in the absence of symptomatology [66].
CIOMS recommend disclosure of ‘‘any finding that
relates to their particular health status’’ [20]. In one US
study, over 90% of neuroimaging volunteers wanted
findings communicated to them [40]. However, some con-
sider it unwise to communicate all but the most certain,
clinically important, incidental findings (Appendix D) [1,
29, 67]. Indeed, in order to comply with US Federal
regulations, researchers should minimise risks to partici-
pants, including the adverse effects of false-positives as
described above [1].
Current practice reflects that both approaches of
disclosing unexpected findings (all findings or ‘‘relevant’’
findings) are commonly used: in a US and European
survey of CT colonography research programmes
(n 5 12), 58% reported all extra-colonic findings and
42% reported ‘‘relevant’’ extra-colonic findings [4].
When not to disclose
The Additional Protocol to the Convention, CIOMS and
other international guidelines from groups including the
‘‘Working Group on Incidental Findings in Brain
Imaging Research’’ recognise that the wishes of indivi-
duals not to be informed should be observed [16, 63, 68].
However, the World Medical Association, which repre-
sents approximately 80 national medical associations,
and the GMC would not respect the refusal by an
individual to receive incidental findings if ‘‘required for
the protection of another person’s life’’ [11, 19]. An
example would be finding a potentially epileptogenic
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brain tumour in a bus driver who happened to be a
research volunteer; even if this person did not wish their
findings be disclosed to them, there is an ethical duty to
do so.
How to disclose
In the UK, DoH and NRES regulations do not state
how incidental findings should be communicated, but
the implication from the DoH is that the participant’s GP
should be involved [10, 13].
In Europe, the Appendix to the Additional Protocol to
the Convention states that relevant incidental findings
should be disclosed within a framework of healthcare or
counselling [17], with an appropriate clinical profes-
sional supervising the research, but not explicitly
disclosing any results themselves.
There is no international consensus on handling and
communicating incidental findings. Contingency plans
may be adequate but non-standardised in up to 47% of
international research groups [8], or sometimes might be
inadequate [30]. Unofficial US contingency guidelines
have recently been published [22]. One of the guidelines
recommends that incidental findings are initially dis-
closed to a participant (or, if they lack capacity, a
surrogate) who controls the information and decides
whom to consult. It recommends that communication is
the responsibility of the principal investigator. If they are
not a clinician, communication may be designated to a
qualified member of the research team, such as a
physician experienced in communication — the pre-
ferred option amongst neuroimaging volunteers [40].
The disadvantage of this guideline is derived from a
whole-body CT screening study in which results were
disclosed to the participant rather than the treating
physician [4]; a third of lesions ‘‘indeterminate, suspi-
cious or highly suggestive of malignancy or life
threatening’’ had not been followed up 5 years later
[69]. In contradistinction to this guideline, other evidence
suggests that communication by the participant’s treat-
ing physician would be appropriate [63] or ideal [70].
The disadvantage of the latter approach is that the
participant may have no control of the information that
could enter their medical record before they have been
consulted, thereby compromising privacy [1].
Another of the US contingency guidelines recom-
mends communicating an incidental finding in a timely
manner consistent with the suspected severity. This
communication should be verbal with written follow-up
drawing on language used in gaining consent [22]. This
approach minimises clinical risk to participants, thereby
complying with US Federal regulations [1].
Satisfactory procedures for disclosure may be costly
and time-consuming. A practical approach for optimis-
ing resources for disclosure may be to use a ‘‘sliding
scale’’, where the mode of communicating incidental
findings to the volunteer (e.g. written, internet, tele-
phone, group or face-to-face) matches their risk and
severity [65].
Discussion
Most of the UK legal and ethical information identified
in this review, and the scant information on volunteers’
expectations, is consistent with the principle that
research volunteers should be informed of how their
research images will be managed, that measures should
be in place for identifying and acting on incidental
findings and that information should be disclosed to the
subject and their responsible physician in a timely,
sensitive and appropriate manner. The wide variation in
practice and opinion, however, suggests that these
regulations and guidelines are interpreted inconsistently.
MDA guidelines on radiological reporting and disclo-
sure of all findings in research MRI are not reflected in
DoH and NRES guidance for ethics committees specifi-
cally on management of research imaging; the degree to
which they are implemented is uncertain, and they do
not in any event apply to other imaging modalities. The
regulations and guidelines are inconsistent, vague or
ambiguous in how they refer to incidental findings,
and lack detail as to how the different stages in the
process should be followed. There is useful additional
guidance in domestic and overseas medical literature
and law.
Further research and discussion is urgently required to
determine optimum practice for identifying incidental
findings and the involvement of radiologists in this
process, as they are an expensive and limited resource.
Reporting of research images by specialist radiologists,
with additional images to improve detection of any
incidental findings, may be best practice. The effects of
incidentally discovered pathology on an individual
subject can be complex and far-reaching. UK guidance
on what constitutes relevant findings and to whom they
should be disclosed is incomplete. European and US
guidelines are more explicit in this regard, but are divided
on whether the subject or their treating physician should
receive this information first. Either way, the best person
to disclose an incidental finding is likely to be a clinician,
the volunteer’s GP or a research clinician experienced in
communicating sensitive medical information.
An approach to good practice derived from this review
is given in Appendix E. However, at national and
international levels, discourse of research practice for
handling incidental findings is needed, with input from
clinical and non-clinical researchers and patients’ repre-
sentatives. In the UK this will allow practical, lawful and
ethically defensible national guidelines to be established
that can inform NRES advice to ethics committees and
set a precedent for other nations.
Summary of this review
N Explicit information on screening for, and handling of,
incidental findings must be provided to participants
as part of the consent process.
N Practice on screening of research images for incidental
findings by radiologists is highly variable. The UK
MDA recommends routine radiological reporting of
all research MRI and disclosure of incidental findings,
but it is unclear how many centres are compliant and
these recommendations do not cover other imaging
modalities.
N There is no general ethical obligation or law in the UK
for incidental findings in volunteers to be disclosed
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to the volunteer, unless the volunteer specifically
requests disclosure. Such requirements are mandated
in European legislation. Volunteers should have the
right not to know of any incidental findings, except if
this places others at risk.
N Any disclosure to a volunteer is best performed by a
medical practitioner experienced in communicating
sensitive medical information. Guidance is divided on
whether the subject or their GP should receive this
information first.
N A discourse of national and international practice is
required in the light of existing legal and ethical
frameworks to develop robust and practical guide-
lines for both research centres and ethics committees
considering proposals for imaging research.
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Appendix A
Summary of criteria [21, 22] for institutional review
board (IRB) approval of radiological research based on US
Food and Drug Administration (FDA) regulations [71, 72]
and Department of Health and Human Services [73].
A caveat is that, according to one author, little
guidance on incidental findings can be derived directly
from these regulations. ‘‘The regulations under which
most IRBs operate were established over 25 years ago
and have not been substantially altered in the interven-
ing years. The technology available today that creates the
opportunity for incidental findings was not conceived of
or considered in the crafting of those regulations.’’ [74]
Appendix B
In 2005 one UK neuroimaging research centre pro-
vided information about consent to volunteers, which
included the following [6]:
Appendix C
Data on the frequency of incidental findings by type of
abnormality, age, sex and other demographics of the
volunteers are limited [3, 36, 75, 76]. However, there is
some detailed breakdown of the 2.7–8.8% intracranial
findings on MRI neuroimaging [2, 5, 30, 34, 75, 77, 78], the
12.8% body findings on whole-bodyMRI [3] and the 5–8%
extra-colonic findings on CT colonoscopy [4]. In the last
case, for example, extra-colonic malignancy was found in
0.6–1.0%. Systematic epidemiological evidence may be
more desirable for producing demographic data (e.g. age
and brain tumour prevalence [79, 80]) as the incidence of
‘‘incidental’’ pathology in research volunteers might be
higher than in the general population. This is because
subjects with symptoms may be more likely to volunteer,
viewing participation in research as an opportunity for a
‘‘free scan’’ [6].
Appendix D
Recommended classification of incidental findings by
US authors [1]. Note that these recommendations were
designed for all volunteers including those undergoing
genetic as well as imaging research. The ‘‘recommended
N Risks to subjects are minimised.
N Risks to subjects are reasonable in relation to anticipated
benefits, if any, to subjects and the importance of the
knowledge that may reasonably be expected to result.
N Selection of subjects is equitable.
N Informed consent will be sought from each prospective
subject or the subject’s legally authorised representative.
N Informed consent will be appropriately documented.
N When appropriate, the research plan makes adequate
provision for monitoring the data collected to ensure the
safety of subjects.
N When appropriate, there are adequate provisions to
protect the privacy of subjects and to maintain the
confidentiality of data.
N A paragraph stating ‘‘there is a chance of less than 1:100
that your MRI scan may show a significant abnormality of
which you are unaware. In such circumstances……you will
be referred to the appropriate specialist in consultation
with your general practitioner, if that is what you would
like. Such early detection has the benefit of starting
treatment early but, in a small number of cases, may have
implications for future employment and insurance.’’
N The authors state any significant abnormality is discussed
with the clinical director of the unit, who is a consultant
neurosurgeon in active clinical practice. The volunteer is
informed that there may be an abnormality and a full
clinical MRI investigation is arranged if necessary.
Volunteers are reassured that no communication will be
made with their family doctor unless they so wish. This is to
avoid data entering the medical records that might be used
at some future date by life insurers and so on.
Category Relevant Incidental Findings Recommended
Action
Strong
Net
Benefit
N Information revealing a
condition likely to be
life-threatening
N Information revealing a
condition likely to be
grave that can be avoided
or ameliorated
N Genetic information revealing
significant risk of a condition
likely to be life-threatening
N Genetic information that
can be used to avoid or
ameliorate a condition likely
to be grave
N Genetic information that can
be used in reproductive
decision-making:
(1) to avoid significant risk for
offspring of a condition likely
to be life-threatening or
grave; or
(2) to ameliorate a condition
likely to be life-threatening
or grave
Disclose to
research volunteer
as an incidental
finding, unless
s/he elected not
to know
Possible
Net
Benefit
N Information revealing a
nonfatal condition that is
likely to be grave or serious
but that cannot be avoided or
ameliorated, when a research
volunteer is likely to deem
that information important
N Genetic information revealing
significant risk of a condition
likely to be grave or serious,
when that risk cannot be
modified but a research volun-
teer is likely to deem that
information important
N Genetic information that is
likely to be deemed important
by a research volunteer and
can be used in reproductive
decision-making:
(1) to avoid significant risk for
offspring of a condition
likely to be serious; or
(2) to ameliorate a condition
likely to be serious
May disclose to
research volunteer
as an incidental
finding, unless
s/he elected not
to know
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actions’’ in the table are contingent on other recommenda-
tions from these authors — that the research protocol and
consent forms anticipate incidental findings and articulate
a bespoke plan for handling them (e.g. to disclose
incidental findings with a strong net benefit, but not to
disclose incidental findings with a possible net benefit).
Appendix E
Category Relevant Incidental Findings Recommended
Action
Unlikely
Net
Benefit
N Information revealing a
condition that is not likely
to be of serious health or
reproductive importance
N Information whose likely
health or reproductive impor-
tance cannot be ascertained
Do not disclose to
research volunteer
as an incidental
finding
Consent
The written consent of the subject is obtained after information on the study is explained to them by someone with
expertise in communicating this information. The information incorporates:
N Possible disadvantages and benefits of taking part including insurance and occupational issues
N What would happen if other conditions were discovered of which he or she was unaware. This includes disclosure
of such information to a medical practitioner who will then disclose this to the participant, and the extent of an
investigator’s responsibility to provide medical services to the participant. The participant chooses one option for
disclosure, which can be changed at any time:
(1) No disclosure of any unexpected finding [except in the interests of public safety]
(2) Disclosure of unexpected findings judged ‘relevant’ (possible or strong net benefit from disclosure). Or
(3) Disclosure of only those incidental findings with a strong net benefit.
N The prevalence of likely incidental findings
N How their confidentiality will be safeguarded during and after the study and the procedures for handling,
processing, storage and destruction of their data match the Caldicott principles and/or the Data Protection Act
1998.
N It must be clear if the data are to be retained for use in future studies and whether further ethics committee
approval will be sought. The participant has an option to allow re-contact in future studies.
A lay group reviews this information and provides feedback to the investigator.
‘Proactive’ reporting
Routine reporting by expert clinical imager who therefore can determine the ‘relevance’ of unexpected findings and
whether there is no, possible or strong net benefit of disclosure to the participant.
Alternatively (and preferably) ‘very proactive’ reporting
Additional images are obtained to optimise this decision making process.
Disclosure
N Timely disclose in accordance with plan articulated during consent
N Disclosure by medical practitioner experienced in communicating sensitive medical information
Q
Q
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